Drug Profile
Rasagiline transdermal patch
Alternative Names: TPU-002RALatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Teikoku Pharma USA
- Class Amines; Antiparkinsonians; Indans; Small molecules
- Mechanism of Action Monoamine oxidase B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for phase-I development in Parkinson's-disease in USA (Transdermal, Patch)
- 14 Apr 2016 Phase-I development is ongoing in USA
- 02 Dec 2014 Phase-I clinical trials in Parkinson's disease in USA (Transdermal)